DAY ONE

8:00 am Check-in Opens & Light Breakfast

8:50 am Chair’s Opening Remarks

  • Rhona Cox Director of Medicinal Chemistry, AstraZeneca

Supercharging RNA Structure Understanding & Target Discovery Using Primary, Secondary & Tertiary Structure Data for Improved Target Prediction

9:00 am Keynote Address: Unlocking RNA Dynamics for Targeted Drug Discovery

Synopsis

Details to be revealed

9:30 am Large-scale Discovery of RNA Tertiary Structures & Disease Relevant RNA Targets

  • Kevin Weeks Professor of Chemistry, Founder, University of North Carolina at Chapel Hill

Synopsis

  • RNA motifs with complex 3D structures are promising targets for small molecule therapeutics but are still very hard to find
  • A new technology that identifies RNA tertiary structures, transcriptome-wide, typically with direct functional roles, will be presented
  • Thousands of targetable sites likely exist across the human transcriptome

10:00 am Leveraging Conformational Dynamics of lncRNAs to Identify Disease Relevant Targets & Selective Small Molecules

  • Alisha Jones Assistant Professor, Chemistry, New York University

Synopsis

  • Investigating conformational dynamics of lncRNAs to understand their structure further for enable better targeting
  • Linking lncRNA target structure to disease to correctly identify disease relevant targets to ensure functional outcomes
  • Identifying small molecules which will sufficiently restrict the RNA target structure to cause a therapeutic effect

10:30 am Morning Break & Speed Networking

Synopsis

This session is your opportunity to get face-to-face with many of the brightest minds working in the RNA Targeting Small Molecule field, and establish meaningful business relationships to pursue for the rest of the conference.

11:30 am NMR as a Tool for Structure Characterization of RNA Targets in Drug Discovery

  • Peter Connolly Vice President - Structural Biology & Biophysics, Expansion Therapeutics

Synopsis

  • Using methods to predict and confirm RNA secondary structure
  • Using NMR to better understand the structure of RNA in structure guided drug design
  • Using NMR in combination with other methods to characterize drug binding on RNA targets

Exploiting Strategies for Accelerating Disease Relevant RNA Target Identification to Ensure Functional Outcomes

12:00 pm New Fluorogenic Toolkits for Diverse RNA-Targeted Drug Discovery Applications

  • Karen Wu Co-Founder & President, Lucerna, Inc.

Synopsis

  • Real-time imaging tools to track RNA movement, measure RNA half-life, and assess RNA target engagement in cells
  • HTS platforms for RNA degradation, splicing, aggregation, and structure-focused hit identification

12:10 pm Panel Discussion: Evaluating High-Value Direct RNA & Protein/RNA Complex Target Traits for Ensuring Efficient Binding & Therapeutic Effect for Accelerating Relevant Drug Discovery

  • Dominic Reynolds Chief Scientific Officer, Remix Therapeutics
  • Domi Stickens Vice President, Discovery Biology & Translational Sciences, Arrakis Therapeutics
  • Paul August Chief Scientific Officer, ReviR Therapeutics
  • Matt Friedersdorf Associate Director, Translational Medicine, Ribometrix

Synopsis

  • What are the key characteristics which validated RNA and RNA/protein targets share?
  • How to conduct high resolution characterization of RNA targets including the different proteins and binding compounds present in the body
  • How to determine RNA sub-targets which can be both bound by small molecule targets and cause therapeutic effects

1:00 pm Lunch & Networking

Discovering Drug-Like Small Molecules with Improved Functional Effects to Fast-Track More Potent Leads Candidates Towards Patients

2:00 pm Genetic Medicines: Discovering Small Molecules that Interdict RNA Function

  • Domi Stickens Vice President, Discovery Biology & Translational Sciences, Arrakis Therapeutics

Synopsis

  • RNA targets are now broadly validated clinically and commercially, but many attractive targets remain out of reach to current modalities
  • Arrakis has built a novel and highly differentiated platform for discovering drug-like small molecule ligands for RNA targets
  • Arrakis platform has thus far produced at least two small molecule programs that clearly mimic the biological activity of oligonucleotide therapeutics

2:30 pm A Complete Workflow for the Identification & Characterization of Small Molecule Modulators of RNA

  • Can Ozbal Founder & Chief Executive Officer, Momentum Biotechnologies

Synopsis

  • A comprehensive workflow starting with approaches to identify small molecules that selectively bind an RNA of interest, determining the binding affinity of binders to target and off-target sequences , and characterization of the functional activity of those binders in cell-based proteomics assays will be presented
  • Additional workflows to quantify and characterize covalent/irreversible adducts of RNA will be also be discussed

3:00 pm Afternoon Networking Break & Scientific Poster Session

Synopsis

Contribute to the conversation and share your cutting-edge research with your fellow RNA[1]targeting community to showcase your breakthrough discoveries to a vast audience of experts. Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

Uncovering Novel Targets on Proteins, Enzymes & RNA/Protein Complexes to Improve Targeting of Disease-Causing RNA for More Efficacious Treatments

4:00 pm Leveraging Strategies to Drug RNA-Protein Complexes with Small Molecule

Synopsis

  • Identifying disease relevant RNA-protein targets for previously intractable diseases
  • Developing screening assay strategies for the discovery of novel small molecule splicing modulators
  • Optimizing toward more potent and efficacious small molecule therapeutics: moving from early discovery to preclinical development for more streamlined translation towards the clinic

4:30 pm RNA-Modifying Enzyme Inhibitors as Synthetic Lethal Cancer Therapeutics

Synopsis

  • Expanding the potential impact of helicase inhibitors beyond MSI-H cancers with DHX9-targeted therapeutics
  • Validation and drug discovery enablement of RNA modifying nuclease target XRN1 in tumors with elevated interferon signaling

5:00 pm Chair’s Closing Remarks & End of Conference Day One

  • Rhona Cox Director of Medicinal Chemistry, AstraZeneca